Aptevo Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
Aptevo Therapeutics Inc. carries a market capitalization of 10.98M, placing it among publicly traded companies globally. Its enterprise value stands at -8.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.98M |
| Enterprise Value | -8.21M |
Share Statistics
Aptevo Therapeutics Inc. currently has 1.20M shares outstanding.
| Shares Outstanding | 1.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | -0.07 |
| P/OCF Ratio | -0.07 |
Financial Position
Aptevo Therapeutics Inc. maintains a current ratio of 3.36, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.36 |
| Quick Ratio | 3.05 |
| Debt / Equity | 38.08 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -185.92 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aptevo Therapeutics Inc.'s stock has declined approximately -94.39419% over the past 52 weeks. The 50-day moving average sits at 4.78, while the 200-day moving average is 15.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.39419% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 15.61 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.45M, while operating income came in at -26.67M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -26.67M |
| Pretax Income | -26.26M |
| Net Income | -26.26M |
| EBITDA | -26.45M |
| EBIT | -26.67M |
| Earnings Per Share (EPS) | -59.37 |
Balance Sheet
Aptevo Therapeutics Inc. holds 14.52M in cash and equivalents against 4.42M in total debt, resulting in a net debt position of -14.52M. Total book value stands at -281.79M, with working capital of 11.22M providing operational flexibility.
| Cash & Cash Equivalents | 14.52M |
| Total Debt | 4.42M |
| Net Debt | -14.52M |
| Equity (Book Value) | -281.79M |
| Book Value Per Share | -637.24 |
| Working Capital | 11.22M |
Cash Flow
Aptevo Therapeutics Inc. produced -26.98M in operating cash flow over the past twelve months.
| Operating Cash Flow | -26.98M |
| Capital Expenditures | N/A |
| Free Cash Flow | -26.98M |
| FCF Per Share | -61.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2,084.90 |
| FCF Yield | -1,428.95 |
Stock Splits
Aptevo Therapeutics Inc.'s most recent stock split took place on December 30, 2025 with a 18:1 split ratio.
| Last Split Date | 12/30/2025 |
| Split Ratio | 18:1 |
Scores
Aptevo Therapeutics Inc. posts an Altman Z-Score of -23.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.44 |